- CVS CEO on the Company's Future One Year After Aetna AcquisitionCVS chief Larry Merlo discussed what's happened in the year since acquiring insurer Aetna—and what comes next.
- The Broader Implications of Biogen's Divisive Alzheimer's DrugAnalyst reactions to Biogen's new Alzheimer's drug data were mixed. But the implications for treating the disease are far broader.
- 5 Health Care Leaders on U.S. Medicine's Trust DeficitIn a wide-ranging dinner conversation, health leaders from Toby Cosgrove to Arianna Huffington discussed why patients don't trust U.S. medicine and data use—and how to fix it.
- The Gene Therapy Spree Rolls on With $3 Billion Astellas DealJapan's Astellas is snatching up Audentes Therapeutics in a $3 billion gene therapy deal—part of a growing trend among pharma companies.
- Trump FDA Nominee Cleared by Senate Panel, Faces Scrutiny on VapingDr. Stephen Hahn was approved by a Senate panel to lead the FDA on Tuesday. But he faced scrutiny on the future of vaping and e-cig regulation.
- Biogen Stock Tumbles on Brutal Takedown of Its Alzheimer's Drug BetBiogen revived an Alzheimer's drug that had been left for dead. But at least one analyst is pouring cold water on the aducanumab bet, and Biogen stock fell Monday.
- Dexcom Software Outage Draws Fury from Diabetes Patients' ParentsDexcom's popular glucose monitoring software alerts went dark over Thanksgiving weekend, enraging the parents of children with diabetes.
Skip to Content